Can long-term zolpidem use lead to dependence and withdrawal if stopped abruptly?

Zolpidem is intended for short-term insomnia treatment, yet sustained exposure can lead to tolerance and physiological dependence. For a 77-year-old, discontinuation should be approached cautiously because older adults are specifically advised to use slow, individualized tapering strategies.

Clinical evidence

• Long-term use can produce tolerance, dependence, rebound insomnia, and withdrawal, particularly with prolonged treatment, dose escalation, or abrupt stopping. Withdrawal may occur even at therapeutic doses, although severe outcomes are concentrated in prolonged supratherapeutic use.
• Abrupt discontinuation can worsen sleep, often on the first night after stopping; sleep generally returns toward baseline by the second night in studied standard-dose populations. Some discontinuation studies met criteria for rebound insomnia, whereas placebo-substitution trials of extended-release zolpidem found no rebound over the first three nights, and a 12-month study found no significant discontinuation-night withdrawal or excess rebound versus placebo.
• A review of published withdrawal cases found symptom onset at a median 30 hours after cessation. Seizures and delirium were reported, but in selected cases with a median zolpidem dose of 200 mg/day, so these severe presentations should not be extrapolated to usual prescribed doses.
• EMA pharmacovigilance data included 23,420 reports involving zolpidem misuse, abuse, dependence, or withdrawal—an important signal, but not an incidence estimate.

Mechanistic evidence

• GABA-A receptor adaptation is a credible but preclinical explanation. In rat neurons after 48 hours of exposure and recombinant cells after 7 days, zolpidem reduced GABA stimulation of benzodiazepine-site binding (“functional uncoupling”) without consistent changes in receptor number or measured subunit transcripts.
• Findings on GABA-A alpha-subunit expression vary by model, brain region, dose, and withdrawal timing; direct confirmation of these adaptations in humans is lacking.

Bottom line

• Long-term zolpidem can cause physiological dependence, and abrupt cessation can cause transient rebound insomnia and withdrawal. Risk is greatest with extended exposure or higher doses; gradual, monitored tapering—potentially supported by CBT-I—is preferable to abrupt discontinuation, especially in older adults.